ArticleInternational journal of women's health2026
Local Triamcinolone Injection versus Anti-Tuberculosis Triple Therapy for Non-Puerperal Mastitis: A Comparative Study.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aims to compare the performance of local triamcinolone injection and anti-tuberculosis triple therapy in treating patients with non-puerperal mastitis (NPM). Methods: This retrospective cohort study included patients diagnosed with NPM at the Breast Surgery Department of the First People's Hospital of Zunyi City between October 2021 and December 2024. Patients were categorized into the triamcinolone group and the anti-tuberculosis group based on the treatment administered. The remission rates, treatment duration, and drug-related adverse reactions were compared between the two groups. Results: A total of 92 cases were included for final analysis, with 44 in the triamcinolone group and 48 in the anti-tuberculosis treatment group. The median treatment duration (41.50 (30.00-60.50) days vs 120.00 (90.00-187.50) days, P < 0.001), and complication rate (13.6% vs 66.7%, P < 0.001) were significantly lower in patients of the triamcinolone group, while the remission rate (91.95 (81.62-100.00)% vs 82.35 (54.55-100.00)%, P = 0.029) and partial remission rate (97.7% vs 68.8%, P < 0.001) were significantly higher. The multivariate logistic regression analysis showed that pathological type (OR = 0.296, 95% CI: 0.091-0.963, P = 0.040) and first affected area (OR = 1.099, 95% CI: 1.025-1.178, P = 0.008) were independent influencing factors of remission rate. Conclusion: Intralesional triamcinolone injection appears to be associated with shorter treatment duration, higher short-term remission rates, and fewer complications compared with antituberculosis triple therapy in patients with NPM. Given the retrospective design, these findings should be validated in prospective randomized studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.